Valuation: Isofol Medical AB

Market Cap 237M 24.13M 21.01M 19.83M 18.02M 33.77M 2.31B 33.91M 91.62M 1.18B 90.64M 88.62M 3.82B P/E 2026 *
-3.89x
P/E 2027 * -24.7x
Enterprise Value 135M 13.75M 11.97M 11.3M 10.27M 19.25M 1.32B 19.33M 52.22M 671M 51.65M 50.51M 2.17B EV / Sales 2026 *
-
EV / Sales 2027 * 3.37x
Free-Float
73.93%
Yield 2026 *
-
Yield 2027 * -
1 day+1.37%
1 week-2.63%
Current month-5.97%
1 month-9.54%
3 months+9.47%
6 months+12.12%
Current year+1.51%
1 week 0.7
Extreme 0.7
0.76
1 month 0.7
Extreme 0.7
0.89
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
0.99
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 2024-01-08
Director of Finance/CFO 60 2024-08-12
Chief Executive Officer 61 2023-06-21
Director TitleAgeSince
Chairman 85 2010-06-30
Director/Board Member 76 2017-12-31
Director/Board Member 78 2024-01-03
Date Insider Type Main position Quantity % Market Cap. Importance
12/10/21 Sell 58,767 0.0364%
12/10/21 Sell 58,767 0.0364%
6/14/21 Others

Chief Financial Officer

15,153 0.0145%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-2.63%-7.50%+12.12% 24.05M
-0.19%+2.04%+80.14%+36.22% 362B
-1.22%-1.22%+20.85%-19.25% 64.74B
+2.53%+4.90%+46.65%+187.52% 12.76B
-0.29%+2.94%-6.00%-16.54% 7.53B
-1.89%-2.14%-27.99%-15.17% 4.38B
-2.06%-4.41%-35.13%+4.31% 4.08B
+1.48%+3.64%-31.47%-15.12% 2.96B
-2.14%+0.86%-8.95%+48.36% 2.44B
-0.41%+1.15%-26.86%-33.47% 1.93B
Average -0.28%+0.19%+0.37%+18.90% 46.32B
Weighted average by Cap. -0.29%+1.57%+65.86%+30.45%

Financials

2026 *2027 *
Net sales - 43.33M 4.41M 3.84M 3.62M 3.29M 6.17M 423M 6.2M 16.74M 215M 16.56M 16.19M 697M
Net income -61.25M -6.23M -5.43M -5.12M -4.65M -8.72M -597M -8.76M -23.66M -304M -23.41M -22.89M -985M -40.15M -4.08M -3.56M -3.36M -3.05M -5.72M -392M -5.74M -15.51M -199M -15.34M -15M -646M
Net Debt -102M -10.38M -9.04M -8.53M -7.75M -14.53M -995M -14.59M -39.4M -506M -38.98M -38.12M -1.64B -91M -9.26M -8.06M -7.61M -6.91M -12.96M -888M -13.01M -35.15M -451M -34.78M -34M -1.46B
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
7
Date Price Change Volume
26-09-18 SEK 0.7400 +1.37% 161,313
26-09-17 SEK 0.7300 +1.96% 95,170
26-09-16 SEK 0.7160 -2.59% 163,643
26-09-15 SEK 0.7350 -0.54% 180,755
26-09-14 SEK 0.7390 -2.76% 182,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!